HS-10504 in Participants With Hepatic Impairment and Normal Hepatic Function

Phase 1, open-label trial of HS-10504 (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Observed Plasma Concentration at 216 hours, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at 216 hours and 1 more. Planned start Sep 2026; status: not yet recruiting.